Isentress

Indications for taking of Isentress.

Treatment of HIV-1 infection in combination with other antiretroviral remedies in adult patients, including if previous antiretroviral therapy is ineffective.

Controlled studies of the remedy Isentress in pregnant women have not been conducted, therefore, Isentress is not recommended to be administered during pregnancy. There is no data on the intake of raltegravir in human breast milk. However, the secretion of raltegravir in milk in rats has been found. When the remedy was administered at a daily dose of 600 mg / kg, the concentration of raltegravir in milk exceeded the plasma concentration by about 3 times. The remedy Isentress should not be administered during lactation. In addition, breastfeeding is not recommended for HIV-infected mothers to avoid postnatal transmission of HIV to children.

Dosing and Administration of Isentress.

The remedy is taken inside. Tablets of Isentress cannot be chewed, crumbled, broken, appointed, regardless of food intake.
Treatment with the remedy Isentress should be performed by a doctor who has sufficient experience in the therapy of HIV infection.
The recommended dose of Isentress for treatment of HIV-1 infection is 400 mg x 2 times a day. Treatment with the remedy Isentress is carried out in combination with other antiretroviral remedies.

Overdose of Isentress.

Specific symptoms of an overdose of the remedy Isentress have not been revealed. Clinical experience shows that raltegravir has a wide therapeutic range and the likelihood of toxic manifestations in overdose is very low. In case of an overdose it is necessary to follow standard recommendations, such as: removal of non-sucking drug from the gastrointestinal tract, monitoring of vital signs, including ECG, the appointment of symptomatic therapy. There is no data on the effectiveness of dialysis in case of an overdose of the remedy Isentress.

Special instructions

Use Isentress with caution in patients at risk of developing myopathy, rhabdomyolysis, and increasing serum CFC concentration.
In the initial stages of combination therapy with antiretrovirals, HIV-infected patients may develop an inflammatory response to asymptomatic or residual opportunistic infections (cytomegalovirus or pneumocystis pneumonia caused by Pneumocystis jiroveci, tuberculosis or paratuberculosis caused by Mycobacterium avium), which can manifest as a worsening of the clinical condition and strengthening of existing symptoms. Usually such reactions are observed in the first weeks or months after the initiation of therapy. In such cases, additional diagnostic and therapeutic measures may be required.
Since it is not known whether Isentress is withdrawn during dialysis, it is not recommended to take a reception on the eve of a dialysis session.